跳至主要内容
临床试验/NCT01748903
NCT01748903Unknown不适用

TARGET Intracranial Aneurysm Coiling Registry: A Prospective Clinical Efficacy and Safety Study of Stryker Target® 360°, Target® Helical, and 2nd Generation Target® Nano Coils

Mercy Health Ohio9 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2013年2月最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
150
试验地点
9
主要终点
Packing Density

研究概览

简要总结

The purpose of this prospective registry is to collect real world, post-marketing data on the use of Stryker Target® 360,Target® 2D, and 2nd generation Target® Nano coils for the embolization of ruptured or unruptured intracranial saccular aneurysms. Up to 300 patients (150 in the TARGET 360°/Helical arm and 150 in the New NANO arm) presenting with intracranial aneurysms suitable for coil embolization will be enrolled at up to 20 sites. A post hoc analysis comparing Target® 360° and Target® 2D coil technical and clinical endpoints will be performed.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient is 18 years or older.
  • Patient has a documented, previously untreated, saccular intracranial aneurysm, unruptured or ruptured, suitable for embolization with coils.
  • (NEW NANO arm ONLY) Target aneurysm is ≤7mm.
  • Patient has a Hunt and Hess Score of 3 or less.
  • Patient has a premorbid mRS of 3 or less.
  • Patient or patient's legally authorized representative has provided written informed consent.
  • Patient is willing to and can comply with study follow-up requirements.

排除标准

  • Patient is < 18 years old.
  • Dissecting aneurysm.
  • Patients with intracranial aneurysms (other than the target aneurysm) that will require treatment during the study period (enrollment through follow-up).
  • Patients in whom the target aneurysm will be treated with coils other than Stryker Target® 360°, Target® Helical coils, and 2nd generation Target® Nano Coils.
  • (NEW NANO Arm ONLY) Patients in whom the target aneurysm was treated with a total coil length comprised of <25% Stryker Target® 2nd generation Nano Coils.
  • Target aneurysm is fusiform.
  • Patients in which the target aneurysm cannot be coiled in one procedure (i.e. staged procedure)

结局指标

主要结局

Packing Density

时间窗: At immediate post-procedure (Day 1)

Packing density will be calculated based on aneurysm volume and amount of coil used during the embolization procedure.

次要结局

  • Aneurysm Re-access Rate(At end of study procedure (Day 1))
  • Modified Rankin Score(At baseline (Day 1) and hospital discharge (Day 3) and 3-9 month follow-up)
  • Treatment-related Morbidity and Mortality(from study procedure (Day 1) to 3-9 month follow-up)
  • Occlusion Rate(At immediate post-procedure (Day 1) and 3-9 month follow-up)
  • Time of Fluoroscopic Exposure(At immediate post-procedure (Day 1))
  • Device-related serious adverse events(From the study procedure (Day 1) until 3-9 month follow up)
  • Length of hospital stay(At hospital discharge (Day 3))
  • Overall Procedure Time(At Immediate post-procedure (Day 1))
  • Aneurysm Recurrence(3-9 month follow-up)
  • Aneurysm Re-treatment Rate(3-9 month follow-up)
  • Aneurysm Bleed and Re-bleed Rate(3-9 month follow-up)
  • Technical and clinical endpoints of Target 360° and 2D coils(3-9 month follow-up)

研究者

发起方
Mercy Health Ohio
申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Osama O. Zaidat

Medical Director, Neuroscience and Stroke Programs

Mercy Health Ohio

研究点 (9)

Loading locations...

相似试验